Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Date:4/29/2009

- Updated Survival and Biomarker Data for Ipilimumab to be Presented -

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical abstracts for ipilimumab in melanoma and prostate cancer, as well as for an anti-PD-1 antibody for cancer treatment, have been selected to be the subject of presentations at the Annual Meeting of the American Society of Clinical Oncology, being held May 29-June 2, 2009 in Orlando:

Survival, Response, Safety and Biomarker Data of Ipilimumab in Melanoma

  • "Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab" (Abstract #9008, Developmental Therapeutics: Immunotherapy Session) O. Hamid - Oral presentation from 1:00 p.m. to 4:15 p.m. local time on Saturday, May 30, 2009.

  • "Increased humoral and cellular immunity in patients (pts) with advanced melanoma treated with ipilimumab" (Abstract #3031, Developmental Therapeutics: Immunotherapy Session) S. Parker - General poster from 8:00 a.m. to 12:00 p.m. local time on Saturday, May 30, 2009.

  • "Effect of ipilimumab treatment on 18-month survival: update of patients with advanced melanoma treated with 10 mg/kg ipilimumab in three Phase II clinical trials" (Abstract #9033, Melanoma Session) S. O'Day - Poster discussion from 8:00 a.m. to 12:00 p.m. local time on Sunday, May 31, 2009.

  • "Immunologic impact of anti-CTLA-4 therapy" (Abstract #3019, Development Therapeutics: Immunotherapy Session) P. Sharma - Poster discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, May 31, 2009.

  • "Association of peripheral blood lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab" (Abstract #3020, Developmental Therapeutics: Immunotherapy Session) D. Berman - Poster discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, May 31, 2009.

  • "Phase 2 trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly known as MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma" (Abstract #9023, Melanoma Session) J. Weber - Poster discussion from 8:00 a.m. to 12:00 p.m. local time on Sunday, May 31, 2009.

  • "Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity" (Abstract #9037, Melanoma Session) A. Amin - General poster from 8:00 a.m. to 12:00 p.m. local time on Monday, June 1, 2009.

  • "Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three Phase 2 clinical trials" (Abstract #9034, Melanoma Session) J. Lutzky - General poster from 8:00 a.m. to 12:00 p.m. local time on Monday, June 1, 2009.

  • "Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors" (Abstract #9036, Melanoma Session) J. Wolchok - General poster from 8:00 a.m. to 12:00 p.m. local time on Monday, June 1, 2009.

  • "Long-term survival in patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine" (Abstract #9038, Melanoma Session) E. Hersh - General poster from 8:00 a.m. to 12:00 p.m. local time on Monday, June 1, 2009.

  • "Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels" (Abstract #9041, Melanoma Session) M. Smylie - General poster from 8:00 a.m. to 12:00 p.m. local time on Monday, June 1, 2009.

Response and Safety Data of Ipilimumab in Prostate

  • "Initial Phase 2 experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)" (Abstract #5138, Genitourinary Cancer - Prostate Session) S. Slovin - General poster from 2:00 p.m. to 6:00 p.m. local time on Sunday, May 31, 2009.

  • "Phase 1 trial of targeted therapy with PSA-TRICOM Vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)" (Abstract #5144, Genitourinary Cancer Session) M. Mohebtash - General poster from 2:00 p.m. to 6:00 p.m. local time on Sunday, May 31, 2009.

Clinical Data of MDX-1106 in Cancer

  • "Phase 2 experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies" (Abstract #3018, Developmental Therapeutics: Immunotherapy Session) J. Brahmer - Poster discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, May 31, 2009.

More information about the ASCO Annual Meeting may be found at www.asco.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved for commercial sale. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at the Needham Cancer Therapeutics Conference
2. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Medarex to Present at the RBC Capital Markets Healthcare Conference
6. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
7. Medarex Announces 2008 Third Quarter Financial Results
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. Medarex to Present at the UBS Global Life Sciences Conference
10. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
11. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 2016 , ... Clinovo , the cloud-based eClinical software ... Capture (EDC) system ClinCaptureand its new Contract Research Organization (CRO) Partner Program ... San Mateo, California on February 10th and 11th. Watch 2-min video . ...
(Date:2/9/2016)...  DNAtrix, a clinical stage, biotechnology company ... its lead product, DNX-2401, has been designated ... medicinal product for the treatment of glioma. ... approximately 25,000 people a year in the ... --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... N.C. , Feb. 8, 2016 Novan, Inc. today ... Chairman of the Board of Directors of Novan. In addition, ... North Carolina . --> ... Company also announced that it received a total of $32.8 million ... 2015 from its private investor network originating throughout the Research Triangle ...
Breaking Biology Technology:
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):